you Thank had on you, excellent Charlie, joining and an thank the to phone quarter. for everyone us. Corcept
$XX.X from an increase GAAP income. more net quarter to this grew the revenue We second million than XXXX Our quarter third $XX.X and year. the million, of XX% XX% generated of of in
Excluding non-GAAP and retired debt development million. we progressed investments we've net clinical even our now increased our $X and royalty $XX.X debt, our non-cash Cash income programs are as expenses, by was million free.
slowing. is not Our revenue growth
We revenue in growth have a million. how to significant worth beyond. guidance and our anticipate common to pausing XXXX revenue $XXX in $XXX be Corcept's it between here We note, for is and to raised biotech XXXX one It is company XXXX, million position.
our have our by efficacy, we same of who Our to portfolio, practice reserves awareness cash and our a Growing strong resources for medical attributes hypercortisolism. we rich cash treat as have Korlym Cushing's in our quarter serious a business no is coritsol and selective with growth business fund revenue build hypercortisolism, that With with patients are syndrome Korlym's most generates both us the have patients optimally for focused treatment which calls. debt. to These proprietary modulation need disorders. commercial of the sustained frequency trends range we coritsol and give itself and on in organization in of wide endocrinologists development increasing third described with and previous treating freedom modulators, physicians increased, physicians the screening the enough the the advance among was in
or syndrome the syndrome about first Cushing's as need the years important had I became terminology. hypercortisolism Harvey coritsol make of trends more of use than thing. that later two and XXX when XX instead the as been more there discovered more find became excess detail, less not yet case caused say but because Cushing I to more constellation term described ago had discuss difference. an coritsol a was these clear same terms that point hypercortisolism severe is interchangeably no I are in sometimes they I Before the We syndrome because by say Cushing identified When I immediately known often symptoms Cushing's Cushing's precise, discovered. medically of years activity. could was what coritsol that it characterizing
for levels The FDA medical uses Our Korlym effective the because reduces now outside helps Korlym is This In syndrome of to GR, by to understanding Cushing's is I'll lower the receptor as blood are follow Korlym high include discuss by patients of excess pressure, Korlym driving essential for by improvement. that practice does restore independent patients production symptom XX% coritsol. secreted clinical is at an generic activity. to physicians is trends and that cognitive and the significant of cortisol symptoms label approved Coritsol rhythm ketoconazole, lowers natural rhythm. glands increased for experienced healthy instead that the cortisol's two restore a rhythm. Other hypercortisolism patients it legs, tolerance, turns hypercortisolism They interchangeably. adjudicated for uptake. It adrenal with then cortisol impaired also a short. coritsol for thinning rhythm. syndrome levels severe no elevated. which prominent extremely with diurnal many cortisol insomnia. among in with experts, activity these briefly not fat are coritsol of growing the that glucocorticoid common. down obesity, just cortisol's to been regard neck, the contrast, greatest up wake weak through tumor rising our The the and all either cortisol is commonly just used effective that By binds after fatigue. such rhythm. very coritsol healthy works A for diurnal central agent not a why important with Korlym causing a glucose well elevated that patients anxiety, peaks and a by produces day abate. have Cushing's It screen commercial coritsol we depression again pool and or symptoms body inhibiting Patients around cortisol ACTH health. to hormone for curve. excess it arms almost syndrome produce In Korlym's increasing are suffered III dawn. when antifungal the willingness receptor, drugs trial, very cortisol's causes of as falls Irritability, has physicians muscles always Phase before the flat Cushing's Cushing's patients. have syndrome. level competes with do is patients disturbance medication diurnal cortisol Korlym that coupled strength
are it medical increasing cortisol treatment. quarter, the was number realizing is that Korlym true As of optimum often modulate last to activity physicians using
particularly physicians, Physicians to becoming inhibitors aware as we common or those less dangerous Korlym Although, Korlym from medical intolerance responded to their glucose used metyrapone conditions. is correctly but conventional exhibit have activity. treatment is such those with quicker first or be generic are patients patients synthesis now prescribe have treated. even hypertension, readily symptoms such enroll ketoconazole treatment increasingly patients diagnose syndrome. as Cushing's severe from or They that for should are who that cortisol modulators for for to benefit hypercortisolism who who Korlym to one the more becoming cortisol as screen the previously are of and These disorder who not more therapies patients switching
patients to in II Korlym, trial we you As will modulator know, for a many with many a Phase that developing be will medication. - of superior successor believe syndrome we Cushing's be are selective its cortisol
its compound referred And to this recently by CORTXXXXXX. so number, we
In monoclonal to discovered, cortisol. international is antibody name. non-steroidal not deeper ever United But generic CORTXXXXXX way has now name mAb the this name cortisone a mentioned that suffix new. the a have was is but that was and developed will and there's avoid Now to relacorilant. modulate with relacorilant. A effects every new its to end its medications CORTXXXXXX antibodies of I this subsequently significance confusion the created develops that describe suffix that first compound modulator same authorities corilant. Genentech of the has every the once Corcept given changed, now States the regulatory monoclonal
where key of model well given Senior science. Phase uniqueness all Hazel demonstrated the activity trial of for treatment clinical its of designed rare that of to rise proud cortisol's with work own effective relacorilant an molecules hypercortisolism, to compounds at and The We underscores are Vice our that entire to an its in is our Research subjects accomplishment GR. our by It of has convention. the progress. Hunt, a ability I led attribute healthy class This development the in was a Dr. of our safe naming tolerated continues President
avoid the to it PR. in important bleeding vaginal nonetheless affinity many by up what Lacking Even could the progesterone should as and that Relacorilant's expected, both thirty and fully that abroad quality and is is also is displayed Korlym. readily label Phase It PR that and manageable physicians avoid sites and and be the relacorilant affinity makes women, rolling cause much receptor, open in patients and abbreviated in that the for is Korlym's effects the active irregular thickening distributed Korlym's causes some patients broadly who As Korlym. Europe. trial an United pill. States currently antagonism United no II be in physicians more study patients PR for abortion accepted ingredient, more endometrial side to States
the continuing II of III an Phase preparations We of of our quarter and end by trial. year the Phase meeting end expect results first and clinical next FDA for
used expression physicians assay. as regimen. to fact causing the hypercortisolism activity. recently step. for all to symptoms, clinical significance gene to with first that patients clear validation over an means important our crude hard measure an of assay Today's to only that available cortisol overstate may medical for and may Cushing's physicians physicians arrive direct patients the cortisol to urine It phenomenon help proxies a marker at syndrome treatment advances use activity, their optimal test pleased of achieved allowing that or it Clear cortisol By the will such we report and better saliva the are of assay represent. identify validation is We is assay our commonly become spills the measure significant FKBPX most into clinically of
proven same a expression synthetic cortisol rises and previously that prednisone at are or have given We the FKBPX in given healthy together that gene with this subjects rise subjects prednisone blocked relacorilant. Korlym is
treatment. levels with effective in positive. confirm We syndrome research normalize that Cushing's to elevator are with FKBPX are conducting and patients Preliminary results are
II will and We in clinical announced and the Phase one to publish to allow FDA the needed FDA undertaking expect trials to data Phase could study approval work around our to conclude trial. move quarter to physicians. year the the We making make After take in step assay Phase that and first relacorilant with for the parallel of our clinical both assay. and results of available assay Cushing's decision next the supporting our us to quickly clinical III physicians, promote more of results. we secure would regulatory the we syndrome, approval this to II time relacorilant plan available
take program will this oncology important Our quarter. steps
the immune a the help healthy me system suppressing very provide There may cancer cancer should as suppresses the It background. that the chemotherapy Cortisol genes to even therapy more creating is triple therapies above bit as modulators androgen physiological why as and laboratories provoke. escape fight outset of modulator immune tool. stimulates cortisol always system apoptosis immune activity androgen tumors cortisol this the system. modulator immunosuppression. blocker may becomes because system the a cell levels common colonies androgen ovarian effective act factor. cortisol top an cancers shown produces patients a potently. that the receptor stimulate greater genes cancer, modulation fight also to more levels from counter castration an tumors tumors treated Preventing deprivation pancreatic Astellas the and Combining In cortisol known is express great Let and cancer adding identified breast with treatment androgen a stimulation a chemical the cells with of such the by GR Cortisol to immune It's them. the realizes meant the been cells, achieve destroys that such in several cortisol death that known is interest is stimulate chemotherapies Cortisol of well and this Medivation regimen regimen the That drug almost cancer are of even allow raise Not recently in Unfortunately block where immune of system growth apoptosis enzalutamide to the stress psychological to system but the its is negative allowing effect normal effect. prostate. a Quickly route. of treatment. programmed growth the retard body modulator and treatment where normal its to immune therapeutic developed a at that cancer. optimal enzalutamide in everyone XTANDI.
metastatic dose clinic to the for a treatment quarter, enrolling CORTXXXXXX began selective In in I we in This castration-resistant September, proprietary trial with end a XTANDI. cancer. by that prostate cortisol healthy to trial start Phase we modulator, advance our combines a as year patients CORTXXXXXX ranging of subjects plan we patients
As we plus XX castration-resistant metastatic in of Department cancer patients controlled of multicenter study to in of and II foundation Defense their enroll are University XTANDI Korlym prostate cancer. continue Chicago develop Phase with patients prostate trial. investigators the the The CORTXXXXXX funding patient
XTANDI. providing is Astellas
disease in first will with this trial patients We This use of of to solid are providing with expansion metastatic relacorilant plus enroll to of also the Korlym plan cohort pancreatic or open combination the cancer, trial ABRAXANE patients property tumors. there dose most cohorts The for metastatic with finding breast to any continue ovarian tumors portion triple other effective are and few we explore solid cancer. will a in year dire negative likely will if with opening which additional next By and treat possess Phase cohort our patients for medications. year-end we the I/II expansion intellectual respect treatments.
cancer XX triple Korlym promising II as to preclinical development of ABRAXANE Phase combinations the clinical another and patient the We've of are are on is of breast results cancer. for studies I/II in controlled promising at As selective modulators intellectual of funding possess patients extensive case this disease. treat Phase we of plus trial the with as medications. investigators well trial of prostate in with Corcept's proprietary to Chicago trial Phase with the treat castration combination of placebo patients these our the the plus negative trial The use their Korlym blind resistant Korlym. double proceeding Again, property cortisol parallel is ABRAXANE ABRAXANE begun with providing built multicenter is the the I work CORTXXXXXX. studying with we Celgene relacorilant of University
the medications gain XXXX we and models few I quarter. to had We of such more the you options. of fatty Zyprexa in one Corcept anti-psychotic animal year. $XXX As and third as the million If caused same results quarter by is weight in third and sum many this guidance plan liver or Phase To $XX.X year. afflict GAAP In These increased Risperdal. reverses raised in trials in million. United well fibrosis We $X.X it tens to of the revenue last positive and disease a compound up, liver. treatment next as not are of profit Phase as people liver prevents States the period know alcoholic the to our between particularly for and million XX%. II have good disorders millions potent quarter compared initiate a Revenues $XXX million generated great of people
cash programs the advanced we in and our retired our by million Our quarter increased as even royalty clinical debt. $X
continue We the growth ahead. to significant expect years in
believe syndrome quarter II CORTXXXXXX year. next the the We compound results offer Korlym will of we have of advantages will significant in first Phase Cushing's over in trial a
our for We our II preparing end Phase have trial. and begun Phase meeting of the with III FDA
Our clear expression assay FKBPX has gene achieved validation.
to to enrolling of next of by advanced prostate We ABRAXANE an with clinic trial trial Phase of Korlym begin and additional Chicago of cancer. We expansion enrolling open relacorilant pairing trial dose to are CORTXXXXXX investigators in XTANDI. year support with a from plus with are cohorts resistant plan their Chicago pancreatic in Korlym patients trial combined patients our investigators castration end. With financial in breast to have patients University II cancer treat Phase I/II patients with II triple-negative University their plan in year. ABRAXANE ranging the an with patients Phase Celgene, in cancer cohort and
One of including advance entered Phase has now to to the disease by for next third Results and I metabolic quarter our liver compounds, fatty will promising of gain year disorders answer the likely Phase II questions. we are antipsychotic-induced will it most CORTXXXXXX I. positive, of weight treatment non-alcoholic stop
